Advair devices progress down the production line at GlaxoSmithKline's manufacturing facility in Zebulon. GSK executives told analysts recently they are bracing for a generic competitor to Advair, whose U.S. patent expires in 2016.
Advair devices progress down the production line at GlaxoSmithKline's manufacturing facility in Zebulon. GSK executives told analysts recently they are bracing for a generic competitor to Advair, whose U.S. patent expires in 2016. Chris Seward cseward@newsobserver.com
Advair devices progress down the production line at GlaxoSmithKline's manufacturing facility in Zebulon. GSK executives told analysts recently they are bracing for a generic competitor to Advair, whose U.S. patent expires in 2016. Chris Seward cseward@newsobserver.com

GSK emerges with smaller, more focused NC presence

June 12, 2015 06:22 PM

UPDATED June 12, 2015 07:09 PM

More Videos

  • Duke engineers create artificial heart muscle for heart attack victims

    Biomedical engineers at Duke have created a fully functioning artificial human heart muscle large enough to patch over damage typically seen in patients who have suffered a heart attack. The advance takes a major step toward the end goal of repairing dead heart muscle in human patients.